Cargando…

Tumor-associated autoantibodies as diagnostic and prognostic biomarkers

In the process of tumorigenesis, normal cells are remodeled to cancer cells and protein expression patterns are changed to those of tumor cells. A newly formed tumor microenvironment elicits the immune system and, as a result, a humoral immune response takes place. Although the tumor antigens are un...

Descripción completa

Detalles Bibliográficos
Autores principales: Heo, Chang-Kyu, Bahk, Young Yil, Cho, Eun-Wie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Biochemistry and Molecular Biology 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133814/
https://www.ncbi.nlm.nih.gov/pubmed/23261052
http://dx.doi.org/10.5483/BMBRep.2012.45.12.236
_version_ 1782330792085553152
author Heo, Chang-Kyu
Bahk, Young Yil
Cho, Eun-Wie
author_facet Heo, Chang-Kyu
Bahk, Young Yil
Cho, Eun-Wie
author_sort Heo, Chang-Kyu
collection PubMed
description In the process of tumorigenesis, normal cells are remodeled to cancer cells and protein expression patterns are changed to those of tumor cells. A newly formed tumor microenvironment elicits the immune system and, as a result, a humoral immune response takes place. Although the tumor antigens are undetectable in sera at the early stage of tumorigenesis, the nature of an antibody amplification response to antigens makes tumor-associated autoantibodies as promising early biomarkers in cancer diagnosis. Moreover, the recent development of proteomic techniques that make neo-epitopes of tumor-associated autoantigens discovered concomitantly has opened a new area of ‘immuno-proteomics’, which presents tumor-associated autoantibody signatures and confers information to redefine the process of tumorigenesis. In this article, the strategies recently used to identify and validate serum autoantibodies are outlined and tumor-associated antigens suggested until now as diagnostic/prognostic biomarkers in various tumor types are reviewed. Also, the meaning of autoantibody signatures and their clinical utility in personalized medicine are discussed. [BMB Reports 2012; 45(12): 677-685]
format Online
Article
Text
id pubmed-4133814
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Korean Society for Biochemistry and Molecular Biology
record_format MEDLINE/PubMed
spelling pubmed-41338142014-09-16 Tumor-associated autoantibodies as diagnostic and prognostic biomarkers Heo, Chang-Kyu Bahk, Young Yil Cho, Eun-Wie BMB Rep Review Article In the process of tumorigenesis, normal cells are remodeled to cancer cells and protein expression patterns are changed to those of tumor cells. A newly formed tumor microenvironment elicits the immune system and, as a result, a humoral immune response takes place. Although the tumor antigens are undetectable in sera at the early stage of tumorigenesis, the nature of an antibody amplification response to antigens makes tumor-associated autoantibodies as promising early biomarkers in cancer diagnosis. Moreover, the recent development of proteomic techniques that make neo-epitopes of tumor-associated autoantigens discovered concomitantly has opened a new area of ‘immuno-proteomics’, which presents tumor-associated autoantibody signatures and confers information to redefine the process of tumorigenesis. In this article, the strategies recently used to identify and validate serum autoantibodies are outlined and tumor-associated antigens suggested until now as diagnostic/prognostic biomarkers in various tumor types are reviewed. Also, the meaning of autoantibody signatures and their clinical utility in personalized medicine are discussed. [BMB Reports 2012; 45(12): 677-685] Korean Society for Biochemistry and Molecular Biology 2012-12 /pmc/articles/PMC4133814/ /pubmed/23261052 http://dx.doi.org/10.5483/BMBRep.2012.45.12.236 Text en Copyright © 2012, Korean Society for Biochemistry and Molecular Biology http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Heo, Chang-Kyu
Bahk, Young Yil
Cho, Eun-Wie
Tumor-associated autoantibodies as diagnostic and prognostic biomarkers
title Tumor-associated autoantibodies as diagnostic and prognostic biomarkers
title_full Tumor-associated autoantibodies as diagnostic and prognostic biomarkers
title_fullStr Tumor-associated autoantibodies as diagnostic and prognostic biomarkers
title_full_unstemmed Tumor-associated autoantibodies as diagnostic and prognostic biomarkers
title_short Tumor-associated autoantibodies as diagnostic and prognostic biomarkers
title_sort tumor-associated autoantibodies as diagnostic and prognostic biomarkers
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133814/
https://www.ncbi.nlm.nih.gov/pubmed/23261052
http://dx.doi.org/10.5483/BMBRep.2012.45.12.236
work_keys_str_mv AT heochangkyu tumorassociatedautoantibodiesasdiagnosticandprognosticbiomarkers
AT bahkyoungyil tumorassociatedautoantibodiesasdiagnosticandprognosticbiomarkers
AT choeunwie tumorassociatedautoantibodiesasdiagnosticandprognosticbiomarkers